Analysts’ Weekly Ratings Updates for Eli Lilly and Company (LLY)

Several brokerages have updated their recommendations and price targets on shares of Eli Lilly and Company (NYSE: LLY) in the last few weeks:

  • 2/7/2024 – Eli Lilly and Company had its price target raised by analysts at Barclays PLC from $680.00 to $810.00. They now have an “overweight” rating on the stock.
  • 2/7/2024 – Eli Lilly and Company had its price target raised by analysts at Morgan Stanley from $763.00 to $805.00. They now have an “overweight” rating on the stock.
  • 2/7/2024 – Eli Lilly and Company had its price target raised by analysts at BMO Capital Markets from $710.00 to $865.00. They now have an “outperform” rating on the stock.
  • 2/7/2024 – Eli Lilly and Company had its price target raised by analysts at Truist Financial Co. from $650.00 to $850.00. They now have a “buy” rating on the stock.
  • 2/6/2024 – Eli Lilly and Company had its price target raised by analysts at Wells Fargo & Company from $700.00 to $825.00. They now have an “overweight” rating on the stock.
  • 2/1/2024 – Eli Lilly and Company had its “overweight” rating reaffirmed by analysts at Cantor Fitzgerald. They now have a $630.00 price target on the stock.
  • 1/24/2024 – Eli Lilly and Company had its price target raised by analysts at Wells Fargo & Company from $650.00 to $700.00. They now have an “overweight” rating on the stock.
  • 1/23/2024 – Eli Lilly and Company had its “overweight” rating reaffirmed by analysts at Cantor Fitzgerald. They now have a $630.00 price target on the stock.
  • 1/23/2024 – Eli Lilly and Company had its price target raised by analysts at Barclays PLC from $630.00 to $680.00. They now have an “overweight” rating on the stock.
  • 1/12/2024 – Eli Lilly and Company had its “overweight” rating reaffirmed by analysts at Cantor Fitzgerald.
  • 12/19/2023 – Eli Lilly and Company had its price target raised by analysts at Morgan Stanley from $727.00 to $822.00. They now have an “overweight” rating on the stock.
  • 12/18/2023 – Eli Lilly and Company had its “overweight” rating reaffirmed by analysts at Cantor Fitzgerald.

Eli Lilly and Company Price Performance

NYSE LLY opened at $737.68 on Tuesday. Eli Lilly and Company has a 52 week low of $309.20 and a 52 week high of $745.70. The company has a current ratio of 1.05, a quick ratio of 0.82 and a debt-to-equity ratio of 1.59. The stock has a market cap of $700.29 billion, a price-to-earnings ratio of 127.19, a price-to-earnings-growth ratio of 2.08 and a beta of 0.32. The company has a 50-day moving average price of $623.06 and a two-hundred day moving average price of $583.91.

Eli Lilly and Company (NYSE:LLYGet Free Report) last posted its quarterly earnings data on Tuesday, February 6th. The company reported $2.49 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.30 by $0.19. The business had revenue of $9.35 billion during the quarter, compared to analysts’ expectations of $8.95 billion. Eli Lilly and Company had a net margin of 15.36% and a return on equity of 50.78%. The business’s revenue was up 28.1% on a year-over-year basis. During the same period last year, the firm posted $2.09 earnings per share. Analysts forecast that Eli Lilly and Company will post 12.52 EPS for the current year.

Eli Lilly and Company Increases Dividend

The firm also recently announced a quarterly dividend, which will be paid on Friday, March 8th. Investors of record on Thursday, February 15th will be paid a dividend of $1.30 per share. The ex-dividend date is Wednesday, February 14th. This is a positive change from Eli Lilly and Company’s previous quarterly dividend of $1.13. This represents a $5.20 annualized dividend and a yield of 0.70%. Eli Lilly and Company’s dividend payout ratio is currently 77.93%.

Insider Activity at Eli Lilly and Company

In related news, major shareholder Lilly Endowment Inc sold 78,573 shares of the stock in a transaction that occurred on Wednesday, January 31st. The shares were sold at an average price of $648.07, for a total transaction of $50,920,804.11. Following the completion of the sale, the insider now directly owns 99,333,810 shares of the company’s stock, valued at $64,375,262,246.70. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Insiders sold a total of 195,055 shares of company stock valued at $125,254,657 over the last ninety days. Insiders own 0.13% of the company’s stock.

Institutional Investors Weigh In On Eli Lilly and Company

Hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Lipe & Dalton purchased a new stake in Eli Lilly and Company in the 4th quarter worth approximately $26,000. Thompson Investment Management Inc. acquired a new position in shares of Eli Lilly and Company during the 3rd quarter worth $27,000. Retirement Group LLC increased its stake in shares of Eli Lilly and Company by 159.1% during the 2nd quarter. Retirement Group LLC now owns 57 shares of the company’s stock worth $27,000 after purchasing an additional 35 shares during the last quarter. Tidemark LLC acquired a new position in shares of Eli Lilly and Company during the 4th quarter worth $29,000. Finally, Cornerstone Planning Group LLC acquired a new position in shares of Eli Lilly and Company during the 2nd quarter worth $33,000. Hedge funds and other institutional investors own 81.38% of the company’s stock.

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. It offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; and Jardiance, Trajenta, and Trulicity for type 2 diabetes.

See Also

Receive News & Ratings for Eli Lilly and Company Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eli Lilly and Company and related companies with MarketBeat.com's FREE daily email newsletter.